All In Biotech

Drug Trial Radar · NCT07858916

A Phase 2b Study to Evaluate the Efficacy, Safety, and PK Profiles of TNP-2092 Administered Via IA Injection in PJI Participants

A Phase 2b, Randomized, Controlled, Open-label Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) Profiles of TNP-2092 Administered Via Intra-articular (IA) Injection on a Background of Antibiotic Treatment in Adult Participants With Early Postoperative or Acute Hematogenous Prosthetic Joint Infection (PJI) After Knee Arthroplasty, Without Debridement, or in Participants With Chronic PJI Requiring Long-term Antibiotic Suppressive Treatment.

Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Oct 21, 2026

Primary completion

Sep 2027

Study completion Mar 2028

Sponsor

Sponsor type
Industry
First posted
Oct 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2b, randomized, controlled, open-label clinical study evaluating the efficacy, safety, and local PK profiles of TNP-2092 administered via IA injection on a background of antibiotic treatment in participants with early postoperative (within 3 months after index arthroplasty) or acute hematogenous (within 4 weeks of infection) PJI after knee arthroplasty, without debridement, and in participants with chronic PJI (including PJI occurring after various joint arthroplasties and revision arthroplasties) requiring long-term antibiotic suppressive treatment.

Conditions

  • Prosthetic Joint Infection (PJI)

Interventions

  • TNP-2092 for injectionDrug

    Starting on D1, administer by intra-articular injection either once daily or once weekly. Participants in Arm A will receive once-daily dosing for 14 days, and participants in Arm B and Arm C will receive once-weekly dosing for 4 weeks. Doses should be administered at approximately the same time whenever possible (no more than 1 hour earlier or later than the time of the first dose).

  • Vancomycin Hydrochloride for InjectionDrug

    Participants receive empiric treatment with vancomycin 1 g administered via IV infusion every 12 hours (q12h). For participants aged 65 years or older, the vancomycin dose may be adjusted to 0.5 g q12h; during the study, it may also be adjusted according to renal function.

  • Oral antibioticsDrug

    After 14 days of IV infusion, participants who meet the criteria for IV to oral switch may switch to oral antibiotic treatment (minocycline or levofloxacin, as determined by the investigator). After 7 days of IV infusion, if IV administration cannot be continued due to tolerability or other reasons, participants may also switch to oral antibiotic treatment if they meet the criteria for IV to oral switch. Oral treatment lasts 56-63 days and combined IV plus oral treatment lasts a total of 10 weeks (70 days). * Levofloxacin tablets: 0.5 g (1 tablet) orally once daily, taken within 1 hour before breakfast, for 56-63 days. * Minocycline hydrochloride capsules: administered orally twice daily; the first dose is 200 mg (2 capsules), and all subsequent doses are 100 mg (1 capsule), for 56-63 days.

  • Appropriate intravenous and/or oral antibioticsDrug

    The investigator will select appropriate intravenous and/or oral antibiotics based on the participant's condition and with reference to domestic and international guidelines, to be continued for 10 weeks (70 days).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment failure rateTime frame: Within 6 months after the initiation of study treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Xinjiang Medical University

    Ürümqi, Xinjiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.